Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for RLAY

Stock NameRelay Therapeutics Inc
TickerRLAY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75943R1023

Show aggregate RLAY holdings

News associated with RLAY

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.25 Consensus PT from Analysts
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the […] - 2025-08-27 02:54:54
XTX Topco Ltd Purchases 20,161 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
XTX Topco Ltd lifted its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 33.7% in the 1st quarter, HoldingsChannel.com reports. The fund owned 79,913 shares of the company’s stock after buying an additional 20,161 shares during the period. XTX Topco Ltd’s holdings in Relay Therapeutics were worth $209,000 as of its most recent […] - 2025-08-14 04:22:55
Raymond James Financial Has Lowered Expectations for Relay Therapeutics (NASDAQ:RLAY) Stock Price
Relay Therapeutics (NASDAQ:RLAY – Free Report) had its target price reduced by Raymond James Financial from $29.00 to $19.00 in a research report report published on Friday morning,Benzinga reports. Raymond James Financial currently has a strong-buy rating on the stock. RLAY has been the subject of several other research reports. Wells Fargo & Company started […] - 2025-08-11 03:50:57
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year […] - 2025-07-30 02:46:52
Relay Therapeutics (NASDAQ:RLAY) versus Incannex Healthcare (NASDAQ:IXHL) Head-To-Head Review
Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability. Institutional & Insider Ownership 0.4% of Incannex […] - 2025-07-29 02:49:02
DekaBank Deutsche Girozentrale Buys 8,937 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
DekaBank Deutsche Girozentrale boosted its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 14.9% during the 1st quarter, HoldingsChannel reports. The fund owned 68,937 shares of the company’s stock after purchasing an additional 8,937 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Relay Therapeutics were worth $181,000 at the end […] - 2025-07-15 06:23:59
Analysts Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $17.67
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The […] - 2025-07-08 02:38:55
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.67 Average Price Target from Analysts
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month […] - 2025-06-13 02:32:49
Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Holdings Boosted by Squarepoint Ops LLC
Squarepoint Ops LLC boosted its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 535.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 162,588 shares of the company’s stock after purchasing an additional 137,020 shares during the quarter. Squarepoint Ops […] - 2025-06-03 05:38:55
Northern Trust Corp Raises Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Northern Trust Corp boosted its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 24.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,169,979 shares of the company’s stock after acquiring an additional 231,713 shares during the quarter. Northern Trust Corp’s holdings in Relay Therapeutics were worth $4,820,000 at the […] - 2025-05-22 04:22:54
Graham Capital Management L.P. Acquires New Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Graham Capital Management L.P. acquired a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 31,569 shares of the company’s stock, valued at approximately $130,000. A number of other large investors have also added to […] - 2025-05-20 05:10:52
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.67 Average PT from Brokerages
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price target […] - 2025-05-19 02:30:55
MetLife Investment Management LLC Acquires 16,477 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
MetLife Investment Management LLC increased its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 28.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 74,166 shares of the company’s stock after buying an additional 16,477 shares during the quarter. MetLife Investment Management LLC’s holdings in Relay Therapeutics were worth $306,000 […] - 2025-05-08 04:56:55
189,046 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by Raymond James Financial Inc.
Raymond James Financial Inc. acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 189,046 shares of the company’s stock, valued at approximately $779,000. Other institutional investors also recently modified their holdings of the company. Barclays PLC lifted its position in shares […] - 2025-05-07 05:46:50
Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Reduced by Wells Fargo & Company MN
Wells Fargo & Company MN trimmed its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 45.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 71,425 shares of the company’s stock after selling 59,042 shares during the period. Wells Fargo & Company MN’s holdings in Relay Therapeutics were worth $294,000 as of […] - 2025-05-07 04:52:58
Renaissance Technologies LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Renaissance Technologies LLC grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 130.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,549,190 shares of the company’s stock after buying an additional 878,095 shares during the […] - 2025-04-20 05:00:52
JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)
JPMorgan Chase & Co. decreased its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 9.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,978,443 shares of the company’s stock after selling 539,073 shares during the period. JPMorgan Chase & […] - 2025-04-11 06:20:51
American Century Companies Inc. Purchases 51,499 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
American Century Companies Inc. increased its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 23.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 272,166 shares of the company’s stock after buying an additional 51,499 shares during the quarter. American Century Companies Inc.’s holdings in Relay Therapeutics were worth $1,121,000 at the […] - 2025-04-11 04:34:48
Prudential Financial Inc. Buys 173,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Prudential Financial Inc. grew its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 45.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 549,645 shares of the company’s stock after acquiring an additional 173,000 shares during the quarter. Prudential Financial […] - 2025-04-04 04:37:00
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Teacher Retirement System of Texas
Teacher Retirement System of Texas grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 19.5% in the fourth quarter, Holdings Channel reports. The fund owned 33,720 shares of the company’s stock after purchasing an additional 5,492 shares during the period. Teacher Retirement System of Texas’ holdings in Relay Therapeutics were worth $139,000 […] - 2025-04-03 04:54:50
Cibc World Markets Corp Buys New Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Cibc World Markets Corp purchased a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 11,388 shares of the company’s stock, valued at approximately $47,000. Several other large investors also recently bought and […] - 2025-03-28 06:18:47
Bank of New York Mellon Corp Purchases 50,190 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Bank of New York Mellon Corp raised its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 18.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 328,897 shares of the company’s stock after acquiring an additional 50,190 shares […] - 2025-03-24 05:10:52
Relay Therapeutics (NASDAQ:RLAY) vs. Kyverna Therapeutics (NASDAQ:KYTX) Financial Survey
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends. Insider & Institutional Ownership 18.1% of Kyverna […] - 2025-03-21 03:51:04
Los Angeles Capital Management LLC Acquires 20,880 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Los Angeles Capital Management LLC increased its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 65.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,770 shares of the company’s stock after purchasing an additional 20,880 shares during the period. […] - 2025-03-05 08:41:42
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by China Universal Asset Management Co. Ltd.
China Universal Asset Management Co. Ltd. raised its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 37.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,491 shares of the company’s stock after purchasing an additional 9,740 shares […] - 2025-02-04 06:53:08

iShares Healthcare Innovation UCITS ETF USD (Acc) RLAY holdings

DateNumber of RLAY Shares HeldBase Market Value of RLAY SharesLocal Market Value of RLAY SharesChange in RLAY Shares HeldChange in RLAY Base ValueCurrent Price per RLAY Share HeldPrevious Price per RLAY Share Held
2025-11-11 (Tuesday)173,221USD 1,089,560RLAY holding increased by 20786USD 1,089,5600USD 20,786 USD 6.29 USD 6.17
2025-11-10 (Monday)173,221USD 1,068,774RLAY holding increased by 20787USD 1,068,7740USD 20,787 USD 6.17 USD 6.05
2025-11-07 (Friday)173,221USD 1,047,987RLAY holding decreased by -83146USD 1,047,9870USD -83,146 USD 6.05 USD 6.53
2025-11-06 (Thursday)173,221USD 1,131,133RLAY holding decreased by -3465USD 1,131,1330USD -3,465 USD 6.53 USD 6.55
2025-11-05 (Wednesday)173,221USD 1,134,598RLAY holding decreased by -53698USD 1,134,5980USD -53,698 USD 6.55 USD 6.86
2025-11-04 (Tuesday)173,221USD 1,188,296RLAY holding decreased by -13858USD 1,188,2960USD -13,858 USD 6.86 USD 6.94
2025-11-03 (Monday)173,221USD 1,202,154RLAY holding decreased by -34644USD 1,202,1540USD -34,644 USD 6.94 USD 7.14
2025-10-31 (Friday)173,221USD 1,236,798RLAY holding decreased by -34644USD 1,236,7980USD -34,644 USD 7.14 USD 7.34
2025-10-30 (Thursday)173,221USD 1,271,442RLAY holding increased by 5196USD 1,271,4420USD 5,196 USD 7.34 USD 7.31
2025-10-29 (Wednesday)173,221USD 1,266,246RLAY holding decreased by -36376USD 1,266,2460USD -36,376 USD 7.31 USD 7.52
2025-10-28 (Tuesday)173,221USD 1,302,622RLAY holding increased by 24251USD 1,302,6220USD 24,251 USD 7.52 USD 7.38
2025-10-27 (Monday)173,221USD 1,278,371RLAY holding increased by 90075USD 1,278,3710USD 90,075 USD 7.38 USD 6.86
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RLAY by Blackrock for IE00BYZK4776

Show aggregate share trades of RLAY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-24SELL-1,4806.8607.500 7.436USD -11,005 3.99 Loss of -5,102 on sale
2025-09-11BUY7524.1204.202 4.194USD 3,154 3.79
2025-07-08SELL-7443.5903.635 3.630USD -2,701 3.80 Profit of 127 on sale
2025-06-24SELL-7653.3103.370 3.364USD -2,573 3.82 Profit of 352 on sale
2025-06-23SELL-7633.2303.250 3.248USD -2,478 3.83 Profit of 443 on sale
2025-06-11SELL-7533.3403.565 3.543USD -2,668 3.86 Profit of 241 on sale
2025-05-30SELL-7573.0003.040 3.036USD -2,298 3.90 Profit of 655 on sale
2025-05-21BUY7572.8603.000 2.986USD 2,260 3.96
2025-05-14SELL-4,5062.7702.880 2.869USD -12,928 4.00 Profit of 5,096 on sale
2025-04-30SELL-7493.3303.470 3.456USD -2,589 4.09 Profit of 472 on sale
2025-04-28SELL-7493.2603.285 3.283USD -2,459 4.11 Profit of 616 on sale
2025-04-25SELL-7493.2003.210 3.209USD -2,404 4.11 Profit of 678 on sale
2025-04-11SELL-3,9782.4202.420 2.420USD -9,627 4.23 Profit of 7,204 on sale
2025-04-08SELL-1,9622.0002.150 2.135USD -4,189 4.30 Profit of 4,252 on sale
2025-04-07SELL-1,3522.0502.080 2.077USD -2,808 4.33 Profit of 3,044 on sale
2025-03-31SELL-1,2822.6202.710 2.701USD -3,463 4.42 Profit of 2,207 on sale
2025-03-21SELL-1,2623.0603.175 3.163USD -3,992 4.54 Profit of 1,736 on sale
2025-03-12SELL-6553.6603.670 3.669USD -2,403 4.65 Profit of 642 on sale
2025-02-28SELL-6513.4103.410 3.410USD -2,220 4.82 Profit of 917 on sale
2025-02-25BUY6513.6803.950 3.923USD 2,554 4.88
2025-02-20SELL-6514.0904.240 4.225USD -2,750 4.93 Profit of 462 on sale
2025-02-19BUY1,2984.1604.160 4.160USD 5,400 4.95
2025-02-18BUY6493.9204.190 4.163USD 2,702 4.97
2024-12-30SELL-1,2294.1804.300 4.288USD -5,270 5.34 Profit of 1,291 on sale
2024-12-06SELL-6174.6104.655 4.651USD -2,869 5.41 Profit of 471 on sale
2024-12-04SELL-6174.3904.590 4.570USD -2,820 5.49 Profit of 569 on sale
2024-12-03SELL-1,2424.3904.670 4.642USD -5,765 5.53 Profit of 1,106 on sale
2024-11-21SELL-6394.6404.760 4.748USD -3,034 5.86 Profit of 712 on sale
2024-11-20SELL-6734.6604.800 4.786USD -3,221 5.93 Profit of 770 on sale
2024-11-19SELL-6694.8004.910 4.899USD -3,277 6.00 Profit of 734 on sale
2024-11-18SELL-2,5004.8905.185 5.155USD -12,889 6.07 Profit of 2,275 on sale
2024-11-12SELL-6255.9406.180 6.156USD -3,847 6.07 Loss of -51 on sale
2024-11-07SELL-6236.1406.480 6.446USD -4,016 6.06 Loss of -241 on sale
2024-11-05SELL-1,2465.9506.000 5.995USD -7,470 6.05 Profit of 70 on sale
2024-10-28SELL-6256.0306.170 6.156USD -3,848 6.32 Profit of 102 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RLAY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19144,6201,200397,05136.4%
2025-09-18380,1924,6201,109,34934.3%
2025-09-17128,4051,740456,01428.2%
2025-09-1696,0038,039417,26623.0%
2025-09-15764,73301,088,95870.2%
2025-09-12137,1631,605418,22832.8%
2025-09-11188,1240352,28553.4%
2025-09-10249,8360607,36541.1%
2025-09-09167,8950300,91055.8%
2025-09-08254,9412,900448,57256.8%
2025-09-05351,6881,300645,60154.5%
2025-09-04289,71235,629726,48839.9%
2025-09-03494,56101,086,09945.5%
2025-09-02204,5640343,17459.6%
2025-08-29129,5250343,95937.7%
2025-08-28159,4750314,27150.7%
2025-08-2770,5080152,82146.1%
2025-08-2696,6080221,80143.6%
2025-08-2578,3170174,18645.0%
2025-08-22170,9440379,00845.1%
2025-08-21103,7900303,93634.1%
2025-08-20185,2191,931412,92144.9%
2025-08-19184,9960365,72250.6%
2025-08-18155,7170295,32252.7%
2025-08-15183,595177459,02140.0%
2025-08-14230,0811595,70138.6%
2025-08-13105,0295440,97623.8%
2025-08-12363,3580741,67449.0%
2025-08-11225,55013,820751,35430.0%
2025-08-081,093,75446,8301,874,16358.4%
2025-08-07227,4860436,97852.1%
2025-08-06183,85745473,12438.9%
2025-08-05102,27616324,67431.5%
2025-08-04138,01401,074,85212.8%
2025-08-01158,96301,364,03511.7%
2025-07-31282,70802,038,33713.9%
2025-07-30123,9730514,80724.1%
2025-07-29280,0062,175995,07428.1%
2025-07-28513,9621,3511,169,00044.0%
2025-07-25251,13632947,12326.5%
2025-07-241,719,2731743,236,36953.1%
2025-07-23189,1492502,686,0727.0%
2025-07-22175,9942,000857,91720.5%
2025-07-21210,138300845,24424.9%
2025-07-18124,716157728,17017.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.